4.4 Article

Hypoxic tumor microenvironment in advanced retinoblastoma

Journal

PEDIATRIC BLOOD & CANCER
Volume 60, Issue 10, Pages 1598-1601

Publisher

WILEY
DOI: 10.1002/pbc.24599

Keywords

CA IX; chemoresistance; HIF-1; hypoxia; retinoblastoma; survivin

Funding

  1. Indian Council of Medical Research (ICMR) [5/4/6/2/2008/NCD-II]

Ask authors/readers for more resources

Purpose Retinoblastoma (RB) is a malignant tumor of infancy and childhood. Unfavorable therapeutic response is still a quest in many tumors, including retinoblastoma. Hypoxic tumor microenvironment is one of the factors that determine the therapeutic response in many tumors. The purpose of this study was to determine the presence of hypoxia and its related proteins; Hypoxia inducible factor-1 (HIF-1), Carbonic anhydrase IX (CA IX) and survivin in RB and their association with clinicopathological features. Materials and Methods We evaluated the expression of HIF-1 and survivin by immunohistochemistry in 42 archival retinoblastoma tumors and CA IX; a hypoxia marker in 33 tumors in the same cohort. The expression was correlated with tumor groups based on invasion, differentiation and IIRC. Results Expression of HIF-1, survivin and CA IX was observed in 83% (35/42), 86% (36/42), and 93% (31/33) of tumors respectively. We observed no significance between HIF-1 and CA IX expression in tumors with invasion, differentiation and in IIRC tumor groups. An increased survivin expression was observed in group E tumors than in group D tumors (P=0.044). A significant association was observed between HIF-1 and survivin in differentiated (r=-0.582; P=<0.01) and undifferentiated tumors groups (r=0.513; P=<0.012). A similar significant association was observed between HIF-1 and CA IX in tumors with high immunoreactivity for HIF-1 (r=0.833; P=<0.01). Conclusion Based on these observations, we propose that HIF-1 pathway is deregulated in RB. The role of drug resistance and the potential of targeting HIF-1, CA IX, and survivin in RB should further examined. Pediatr Blood Cancer 2013;60:1598-1601. (c) 2013 Wiley Periodicals, Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available